课题基金 / 基金详情

项目摘要

项目成果

Grace M Aldrovandi的其他基金

相关文献

中文摘要
翻译
摘要 艾滋病临床试验组 (ACTG) 已被选为领导主自适应方案的领导者 加速 COVID-19 治疗干预和疫苗 (ACTIV) 操作的极速运行。本次审判 (ACTG 5401或ACTIV-2)将评估门诊患者的多种单克隆抗体和其他小分子 新冠肺炎治疗。实验室中心将扩大其工作范围,包括对 COVID-19 临床试验的支持。
英文摘要
ABSTRACT The AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core C -Centralized Laboratory Support Core
Study of Tecovirimat for Human Monkeypox Virus (STOMP)
Core C -Centralized Laboratory Support Core
Effects of Human Milk Oligosaccharides and Gut Microbiome on Growth and Morbidity in HIV-Exposed Uninfected Infants
  • 批准号:
    9920737
  • 项目类别:
  • 资助金额:
    $70.86万
  • 财政年份:
    2019
  • 负责人:
    Grace M Aldrovandi
  • 依托单位: